Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech binary events -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (50)	6/5/2003 11:18:49 AM
From: Biomaven	Read Replies (1) \| Respond to of 295

historic survival rates for metastatic disease prior to the availability of immunotherapy ? The trouble is you need more than median survival and 5-year survival, which is all that is usually quoted. The paper I quoted actually has the right curves - it's just that this current trial is starting mid-way along their curves, after people have already failed, and I don't know how far along to start. Also now that I think about it some more, I presumably need to exclude their long-term survivors altogether, because I assume they didn't ever show progression. So maybe the long tails in my article are deceiving. On another issue altogether, anyone have any idea of what the IP protection here is? Further, are they offering anything more than the same shark gloop you can buy at health food stores? See, for example: realife.com Peter P.S. Don't know if we should take this discussion to another thread or not. I assume this one is low-profile enough so that we aren't actually bothering anyone here.